MedTrace Logo

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 217

Last updated 2026-01-07

No results posted yet for this study

Summary

The main purpose of the study is to evaluate safety and efficacy of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Taletrectinib

400mg or 600mg QD

Sponsors & Collaborators

  • Nuvation Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Wei Wang, MD, PhD · Nuvation Bio Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2025-06-11
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • China
  • France
  • Italy
  • Japan
  • Poland
  • South Korea
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04919811 on ClinicalTrials.gov